As U.S. Slashes $500M in mRNA Funding, Bordeaux Biotech bYoRNA Raises €1.5M to Reinvent RNA Production

bYoRNA is developing a patented fermentation process that could cut RNA production costs by 100x, improve safety, and enable global access to next-generation vaccines and therapies. This breakthrough comes as the U.S. is rejecting mRNA, a move that complicates the startup's business strategy.